Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Payables: 2014-2024

Historic Payables for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to $9.8 million.

  • Viking Therapeutics' Payables rose 1637.40% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.4 million, marking a year-over-year increase of 13.87%. This contributed to the annual value of $9.8 million for FY2024, which is 30.63% up from last year.
  • Latest data reveals that Viking Therapeutics reported Payables of $9.8 million as of FY2024, which was up 30.63% from $7.5 million recorded in FY2023.
  • Viking Therapeutics' 5-year Payables high stood at $9.8 million for FY2024, and its period low was $1.4 million during FY2021.
  • Its 3-year average for Payables is $8.6 million, with a median of $8.5 million in 2022.
  • As far as peak fluctuations go, Viking Therapeutics' Payables crashed by 63.79% in 2021, and later spiked by 490.65% in 2022.
  • Over the past 5 years, Viking Therapeutics' Payables (Yearly) stood at $4.0 million in 2020, then slumped by 63.79% to $1.4 million in 2021, then soared by 490.65% to $8.5 million in 2022, then fell by 11.92% to $7.5 million in 2023, then spiked by 30.63% to $9.8 million in 2024.